Real-world study of atezolizumab for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how well atezolizumab works for people with stage IV non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). It's for people getting atezolizumab as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer.
- You are 18 years or older.
- You have been prescribed atezolizumab as your first treatment.
- You have received up to 3 cycles of atezolizumab so far.
- You are not pregnant or breastfeeding.
- You have no known allergies to atezolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
This trial is testing a combination of two drugs, cabozantinib and atezolizumab, for people with advanced lung cancer that has low PD-L1 levels. The goal is to see if this combination can shrink tumors and help control the cancer.
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
This trial tests a drug called atezolizumab, which helps the immune system fight cancer, for people with advanced lung cancer (non-small cell lung cancer) that has not been treated yet. It is for tumors with high levels of PD-L1, a protein that can help cancer hide from the immune system.
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.